Development of an optimized dosing regimen of ceftazidime-avibactam in critically ill patients treated with continuous renal replacement therapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505536-35-00

Enrollment

Registered

2025-01-24

Start date

2025-05-04

Completion date

Unknown

Last updated

2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ceftazidime-avibactam therapy in critically ill patients undergoing continuous renal replacement therapy

Brief summary

Pharmacokinetic parameters of ceftazidime and avibactam, PK/PD target attainment of ceftazidime and avibactam, Population PK model of ceftazidime-avibactam, Optimized ceftazidime-avibactam dosing regimen

Interventions

DRUGCEFTAZIDIME AND BETA-LACTAMASE INHIBITOR

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters of ceftazidime and avibactam, PK/PD target attainment of ceftazidime and avibactam, Population PK model of ceftazidime-avibactam, Optimized ceftazidime-avibactam dosing regimen	—

Countries

Belgium, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026